Pyxis Oncology, Inc.
PYXS
$3.38
-$0.51-13.11%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -88.73M | -81.74M | -79.62M | -97.09M | -96.29M |
| Total Depreciation and Amortization | 4.18M | 4.42M | 4.51M | 2.16M | 2.37M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 11.45M | 8.20M | 9.67M | 30.13M | 28.89M |
| Change in Net Operating Assets | 5.18M | 2.15M | 1.94M | -7.57M | -8.72M |
| Cash from Operations | -67.91M | -66.97M | -63.50M | -72.37M | -73.75M |
| Capital Expenditure | -9.00K | -9.00K | -9.00K | -9.00K | 0.00 |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 65.41M | 59.41M | 58.87M | 69.26M | 57.77M |
| Cash from Investing | 65.40M | 59.41M | 58.86M | 69.25M | 57.77M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 10.79M | 740.00K | 742.00K | 2.00K | 1.66M |
| Repurchase of Common Stock | -157.00K | -171.00K | -148.00K | -7.73M | -7.72M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 7.70M | 7.70M |
| Cash from Financing | 10.63M | 569.00K | 594.00K | -25.00K | 1.64M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 8.12M | -6.99M | -4.05M | -3.14M | -14.34M |